×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
OTCMKTS:RSLS

ReShape Lifesciences Stock Forecast, Price & News

$0.62
+0.02 (+3.34%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.60
$0.63
50-Day Range
$0.60
$1.12
52-Week Range
$0.56
$8.05
Volume
114,748 shs
Average Volume
322,228 shs
Market Capitalization
$11.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75
30 days | 90 days | 365 days | Advanced Chart

Receive RSLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

RSLS Stock Forecast (MarketRank)

Overall MarketRank

2.04 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
ReShape Lifesciences logo

About ReShape Lifesciences (OTCMKTS:RSLS)

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

RSLS Stock News Headlines

ReShape Lifesciences Inc. (RSLS)
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
OTCMKTS:RSLS
CUSIP
29365M20
Fax
N/A
Employees
47
Year Founded
N/A

Company Calendar

Last Earnings
5/23/2022
Today
6/25/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$4.75
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+668.0%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$-61.93 million
Net Margins
-716.12%
Pretax Margin
-719.28%

Debt

Sales & Book Value

Annual Sales
$13.60 million
Book Value
$2.59 per share

Miscellaneous

Free Float
18,645,000
Market Cap
$11.54 million
Optionable
Not Optionable
Beta
-0.61














ReShape Lifesciences Frequently Asked Questions

Should I buy or sell ReShape Lifesciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ReShape Lifesciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ReShape Lifesciences stock.
View analyst ratings for ReShape Lifesciences
or view top-rated stocks.

What is ReShape Lifesciences' stock price forecast for 2022?

2 Wall Street research analysts have issued twelve-month price targets for ReShape Lifesciences' shares. Their RSLS stock forecasts range from $4.00 to $5.50. On average, they anticipate ReShape Lifesciences' stock price to reach $4.75 in the next year. This suggests a possible upside of 668.0% from the stock's current price.
View analysts' price targets for ReShape Lifesciences
or view top-rated stocks among Wall Street analysts.

How has ReShape Lifesciences' stock performed in 2022?

ReShape Lifesciences' stock was trading at $1.64 on January 1st, 2022. Since then, RSLS stock has decreased by 62.3% and is now trading at $0.6185.
View the best growth stocks for 2022 here
.

How were ReShape Lifesciences' earnings last quarter?

ReShape Lifesciences Inc. (OTCMKTS:RSLS) released its earnings results on Monday, May, 23rd. The medical device company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.10. The medical device company had revenue of $2.44 million for the quarter. ReShape Lifesciences had a negative net margin of 716.12% and a negative trailing twelve-month return on equity of 49.28%.
View ReShape Lifesciences' earnings history
.

When did ReShape Lifesciences' stock split? How did ReShape Lifesciences' stock split work?

Shares of ReShape Lifesciences reverse split on Thursday, November 8th 2018. The 1-140 reverse split was announced on Wednesday, November 7th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 7th 2018. An investor that had 100 shares of ReShape Lifesciences stock prior to the reverse split would have 1 shares after the split.

Who are ReShape Lifesciences' key executives?

ReShape Lifesciences' management team includes the following people:
  • Mr. Barton P. Bandy, Pres, CEO & Director (Age 61, Pay $377k) (LinkedIn Profile)
  • Mr. Thomas Stankovich, Sr. VP of Fin. & CFO (Age 61, Pay $290k) (LinkedIn Profile)
  • Dr. Mark B. Knudson Ph.D., Co-Founder and Special Advisor to the CEO (Age 73)
  • Dr. Katherine S. Tweden Ph.D., Co-Founder (Age 61)
  • Mr. Al Diaz, VP of Operations and R&D
  • Dr. Rajesh Nihalani, Chief Technology Officer & Bus. Devel. (Age 52)
  • Dr. Dov Gal D.V.M., DVM, M.B.A., MBA, VP of Regulatory & Clinical Affairs and Compliance Officer
  • Jody B. Dahlman, Director of Communications
  • Mr. Kevin Condrin, Sr. VP of Market Devel. & Integration
  • Mr. Michael Bordainick, Sr. VP of Commercial Operations

What other stocks do shareholders of ReShape Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReShape Lifesciences investors own include XOMA (xoma), CTI BioPharma (CTIC), Synergy Pharmaceuticals (SGYP), DryShips (DRYS), La Jolla Pharmaceutical (LJPC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Neovasc (NVCN), Clovis Oncology (CLVS) and CytRx (CYTR).

What is ReShape Lifesciences' stock symbol?

ReShape Lifesciences trades on the OTCMKTS under the ticker symbol "RSLS."

Who are ReShape Lifesciences' major shareholders?

ReShape Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (0.20%). Company insiders that own ReShape Lifesciences stock include Armistice Capital Master Fund, Armistice Capital, Llc, Barton P Bandy, Barton P Bandy, Dan W Gladney and Thomas Stankovich.
View institutional ownership trends for ReShape Lifesciences
.

Which major investors are buying ReShape Lifesciences stock?

RSLS stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP. Company insiders that have bought ReShape Lifesciences stock in the last two years include Armistice Capital Master Fund, and Thomas Stankovich.
View insider buying and selling activity for ReShape Lifesciences
or or view top insider-buying stocks.

How do I buy shares of ReShape Lifesciences?

Shares of RSLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ReShape Lifesciences' stock price today?

One share of RSLS stock can currently be purchased for approximately $0.62.

How much money does ReShape Lifesciences make?

ReShape Lifesciences (OTCMKTS:RSLS) has a market capitalization of $11.54 million and generates $13.60 million in revenue each year. The medical device company earns $-61.93 million in net income (profit) each year or ($4.88) on an earnings per share basis.

How many employees does ReShape Lifesciences have?

ReShape Lifesciences employs 47 workers across the globe.

How can I contact ReShape Lifesciences?

ReShape Lifesciences' mailing address is 1001 Calle Amanecer, San Clemente CA, 92673. The official website for ReShape Lifesciences is www.reshapelifesciences.com. The medical device company can be reached via phone at (949) 429-6680 or via email at [email protected].

This page (OTCMKTS:RSLS) was last updated on 6/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.